The White House has recently announced that two new major drug companies are joining the TrumpRx platform, bringing the total medications offered to 54 – amid skepticism among naysayers saying the drug-discount site would not be beneficial. 

Since the initial announcement of the program by President Donald Trump in February, TrumpRx.gov has expanded significantly with the recent integration of products from two additional major pharmaceutical manufacturers, Amgen and GSK. 

The additions include key treatments such as Amgen's Amjevita (a biosimilar for conditions like rheumatoid arthritis, psoriasis, and ulcerative colitis); Aimovig for migraines; and Repatha for high cholesterol, alongside GSK's respiratory medications including Incruse Ellipta, Arnuity Ellipta, Anoro Ellipta and Relenza for influenza. 

"President Trump is delivering on promises to ensure American patients no longer pay high prices to subsidize low prices in the rest of the world, something the political establishment did not believe was possible," the White House said Feb. 5 in announcing the additions. 

The platform now features a total of 54 discounted prescription medications available from six participating companies overall. The website offers an updated catalog, price comparisons, and an option to sign up for notifications about future expansions.

As a result of the drug availability on the site, many Americans are experiencing substantial and immediate reductions in out-of-pocket expenses for a variety of essential and high-cost therapies now accessible through TrumpRx.gov, resulting in a tangible impact on affordability, one of Trump's hallmark issues. 

Amgen's Amjevita autoinjector is now priced at $299, representing an 80% discount from its previous list price of $1,484.16, making advanced autoimmune treatments far more attainable for patients without comprehensive insurance coverage. 

GSK's Incruse Ellipta inhaler, commonly used for chronic obstructive pulmonary disease (COPD), has been reduced to $159.20, a 55% savings from $354.10, while other GSK options include Arnuity Ellipta starting at $102.98 (51% off) and Anoro Ellipta at $247.94 (49% off). 

Additional notable savings extend to drugs like Amgen's Aimovig and Repatha at $299 and $239 respectively (both around 62 percent reductions), as well as broader offerings such as fertility treatments and weight-loss medications, allowing individuals to bypass traditional insurance barriers and access critical care at dramatically lower cash-pay rates.

The TrumpRx initiative aligns with Trump's broader strategy of implementing Most-Favored-Nation (MFN) pricing to align U.S. drug costs with the lowest rates paid in other developed countries, taking a significant step toward systemic healthcare reform. 

More than 16 pharmaceutical companies have now entered pricing agreements with the administration to support the platform's ongoing expansion and deliver sustained consumer benefits. 

Administration officials have emphasized that these partnerships are foundational, with expectations of further substantial discounts, reduced insurance premiums, and increased pricing transparency as related congressional legislation, including elements of the Great Healthcare Plan, progresses in the coming months. 

When launched last month, the site featured 43 medications from the initial five partners. Since then, the site has grown rapidly to its current scale of 54 drugs, underscoring accelerating momentum and the effectiveness of direct government-led pressure on the industry to prioritize American patients.

Among the critics of the program are Democrats on the House Energy and Commerce Committee.

“TrumpRx is all hype and no true action,” New York Rep. Frank Pallone, the committee's top Democrat, said in Feb. 24 report by his caucus. “At best, the platform offers discount coupons that are readily available elsewhere. At worst, it appears to intentionally withhold information about more affordable generic alternatives and in some instances even charges consumers more than if they purchased the drug directly from the manufacturer.